DATA GRAPHICS | Data Byte
Immunology companies acquired by pharmas in 2020-23
At least 13 immunology-focused biotechs have been acquired for ≥$1B since start of 2020, with three of the deals announced this year
September 20, 2023 7:58 PM UTC
Of the seven major pharmas that announced acquisitions of autoimmune or inflammatory disease companies since the start of 2020, Sanofi was the most frequent buyer but not the biggest spender.
Out of the 13 M&A deals identified by BioCentury in which a pharma company agreed to acquire an immunology-focused biotech for at least $1 billion, Sanofi (Euronext:SAN; NASDAQ:SNY) accounted for four (30%), and Amgen Inc. (NASDAQ:AMGN), Eli Lilly and Co. (NYSE:LLY) and Merck & Co. Inc. (NYSE:MRK) each accounted for two...
BCIQ Company Profiles